1. Home
  2. BTCT vs IMRN Comparison

BTCT vs IMRN Comparison

Compare BTCT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

SELL

Current Price

$0.56

Market Cap

7.5M

Sector

Real Estate

ML Signal

SELL

Logo Immuron Limited

IMRN

Immuron Limited

SELL

Current Price

$0.89

Market Cap

7.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BTCT
IMRN
Founded
2006
1994
Country
Singapore
Australia
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.7M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
BTCT
IMRN
Price
$0.56
$0.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 253.5K
15.8K
Earning Date
11-27-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$1.58
$12.00
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.68
52 Week High
$2.75
$1.99

Technical Indicators

Market Signals
Indicator
BTCT
IMRN
Relative Strength Index (RSI) 34.27 45.85
Support Level $0.50 $0.90
Resistance Level $1.21 $1.00
Average True Range (ATR) 0.06 0.06
MACD 0.01 0.01
Stochastic Oscillator 4.48 71.32

Price Performance

Historical Comparison
BTCT
IMRN

About BTCT BTC Digital Ltd.

BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.

About IMRN Immuron Limited

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Share on Social Networks: